Prevalence of anti HCV, HBsAg and HIV antibodies in high risk recipients of blood and blood products.
Along with hepatitis B virus (HBV) and human immunodeficiency virus (HIV), Hepatitis C virus (HCV) is emerging as a major transfusion hazard. 22 cases of haemophilia (A 19, B 3) and 20 cases of thalassaemia (2 16, E(2) 4) constituted the study group. Patients tested for anti HCV (using third generation ELISA), HBsAg and antibodies to HIV I and II. Prevalence of anti HCV was 54.5% in haemophilics and 5% in thalassaemics. HBsAg was detected in 9.09% haemophilics and 5% thalassaemics. No anti HIV was detected in this cohort. Anti HCV seropositivity in haemophilics has increased compare to previous studies.
Chakrabarti
S
S
Dept. of Pathology, NRS Medical College. sudiptach@gmail.com
Pradhan
P
P
Roy
A
A
Hira
M
M
Bandyopadhyay
G
G
Bhattacharya
D K
DK
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D006678:HIV / Q000276:immunology*; D006467:Hemophilia A / Q000628:therapy*; D016174:Hepacivirus / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006526:Hepatitis C / Q000635:transmission*; D006801:Humans; D015995:Prevalence; D016036:Seroepidemiologic Studies; D013789:Thalassemia / Q000628:therapy*; D065227:Transfusion Reaction
D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens